Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Standard

Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy. / Egeberg, A.; Meteran, H.; Gyldenløve, M.; Zachariae, C.

I: British Journal of Dermatology, Bind 185, Nr. 6, 2021, s. 1251-1252.

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Harvard

Egeberg, A, Meteran, H, Gyldenløve, M & Zachariae, C 2021, 'Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy', British Journal of Dermatology, bind 185, nr. 6, s. 1251-1252. https://doi.org/10.1111/bjd.20602

APA

Egeberg, A., Meteran, H., Gyldenløve, M., & Zachariae, C. (2021). Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy. British Journal of Dermatology, 185(6), 1251-1252. https://doi.org/10.1111/bjd.20602

Vancouver

Egeberg A, Meteran H, Gyldenløve M, Zachariae C. Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy. British Journal of Dermatology. 2021;185(6):1251-1252. https://doi.org/10.1111/bjd.20602

Author

Egeberg, A. ; Meteran, H. ; Gyldenløve, M. ; Zachariae, C. / Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy. I: British Journal of Dermatology. 2021 ; Bind 185, Nr. 6. s. 1251-1252.

Bibtex

@article{742c570167f14f35b1a8b4c1db136d54,
title = "Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy",
abstract = "Current psoriasis therapies have little-to-no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE-4) inhibitor, is approved for moderate-to-severe psoriasis and considered a safe treatment option, that does not require laboratory monitoring. Nonetheless, lower efficacy compared with novel similar priced biologics, have led to modest use of apremilast in some countries. Roflumilast, a selective oral PDE-4 inhibitor, is approved for severe COPD in the US and EU. A common side effect of roflumilast therapy is weight loss, which has limited its use in COPD, where underweight is frequently observed.",
author = "A. Egeberg and H. Meteran and M. Gyldenl{\o}ve and C. Zachariae",
year = "2021",
doi = "10.1111/bjd.20602",
language = "English",
volume = "185",
pages = "1251--1252",
journal = "British Journal of Dermatology, Supplement",
issn = "0366-077X",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy

AU - Egeberg, A.

AU - Meteran, H.

AU - Gyldenløve, M.

AU - Zachariae, C.

PY - 2021

Y1 - 2021

N2 - Current psoriasis therapies have little-to-no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE-4) inhibitor, is approved for moderate-to-severe psoriasis and considered a safe treatment option, that does not require laboratory monitoring. Nonetheless, lower efficacy compared with novel similar priced biologics, have led to modest use of apremilast in some countries. Roflumilast, a selective oral PDE-4 inhibitor, is approved for severe COPD in the US and EU. A common side effect of roflumilast therapy is weight loss, which has limited its use in COPD, where underweight is frequently observed.

AB - Current psoriasis therapies have little-to-no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE-4) inhibitor, is approved for moderate-to-severe psoriasis and considered a safe treatment option, that does not require laboratory monitoring. Nonetheless, lower efficacy compared with novel similar priced biologics, have led to modest use of apremilast in some countries. Roflumilast, a selective oral PDE-4 inhibitor, is approved for severe COPD in the US and EU. A common side effect of roflumilast therapy is weight loss, which has limited its use in COPD, where underweight is frequently observed.

U2 - 10.1111/bjd.20602

DO - 10.1111/bjd.20602

M3 - Letter

C2 - 34184248

VL - 185

SP - 1251

EP - 1252

JO - British Journal of Dermatology, Supplement

JF - British Journal of Dermatology, Supplement

SN - 0366-077X

IS - 6

ER -

ID: 276230941